Stem Cell Therapy in Critical Limb Ischemia.
amputation rates
critical limb ischemia
ischemia
mononuclear cells
stem cell
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
accepted:
10
07
2023
medline:
14
8
2023
pubmed:
14
8
2023
entrez:
14
8
2023
Statut:
epublish
Résumé
Critical limb ischemia (CLI), a serious outcome of peripheral artery disease, is frequently associated with morbid outcomes. The available treatment modalities do not provide satisfactory results, leading to marked morbidities such as joint contracture and amputations, resulting in a high economic burden. The peripheral vascular disease tends to cause more morbidity in patients with diabetes and atherosclerosis, given the pre-existing compromised perfusion of medium and small vessels in diabetic patients. With surgical procedures, the chance of vascular compromise further increases, inducing a significantly greater rate of amputation. Hence, the need for nonsurgical treatment modalities such as stem cell therapy (SCT), which promotes angiogenesis, is warranted. In CLI, SCT acts through neovascularization and the development of collateral arteries, which increases blood supply to the soft tissues of the ischemic limb, providing satisfactory outcomes. An electronic database search was performed in PubMed, SCOPUS, EMBASE, and ScienceDirect to identify published clinical trial data, research studies, and review articles on stem cell therapy in critical limb ischemia. The search resulted in a total of 2391 results. Duplicate articles screening resulted in 565 articles. In-depth screening of abstracts and research titles excluded 520 articles, yielding 45 articles suitable for full-text review. On review of full text, articles with overlapping and similar results were filtered, ending in 25 articles. SCT promotes arteriogenesis, and bone marrow-derived mesenchymal stromal cells produce significant effects like reduced morbidity, improved amputation-free survival (AFS ) rate, and improved distal perfusion even in "no-option" CLI patients. SCT is a promising treatment modality for CLI patients, even in those in whom endovascular and revascularization procedures are impossible. SCT assures a prolonged AFS rate, improved distal perfusion, improved walking distances, reduced amputation rates, and increased survival ratio, and is well-tolerated.
Identifiants
pubmed: 37575721
doi: 10.7759/cureus.41772
pmc: PMC10416751
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e41772Informations de copyright
Copyright © 2023, Jeyaraman et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Circ Cardiovasc Interv. 2012 Dec;5(6):821-30
pubmed: 23192920
Nat Med. 2003 Nov;9(11):1370-6
pubmed: 14556003
Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14537-41
pubmed: 16983080
Science. 1998 Nov 6;282(5391):1145-7
pubmed: 9804556
Vasc Health Risk Manag. 2019 Jul 01;15:187-208
pubmed: 31308682
Ann Vasc Dis. 2018 Dec 25;11(4):449-457
pubmed: 30636998
Stem Cells Int. 2017;2017:3750829
pubmed: 29358955
Stem Cells Int. 2015;2015:931420
pubmed: 26300924
PLoS One. 2013;8(4):e60161
pubmed: 23560074
J Vasc Surg. 2014 Sep;60(3):686-95.e2
pubmed: 24820900
Stem Cells. 2006 Oct;24(10):2309-18
pubmed: 16794267
Int J Mol Sci. 2019 Nov 14;20(22):
pubmed: 31739395
Curr Pharm Des. 2007;13(17):1811-24
pubmed: 17584110
J Vasc Surg. 2007 Jun;45 Suppl A:A39-47
pubmed: 17544023
Am J Physiol Heart Circ Physiol. 2007 Jan;292(1):H657-65
pubmed: 16997894
Adv Healthc Mater. 2019 Oct;8(20):e1900967
pubmed: 31557404
Orv Hetil. 2006 Jun 25;147(25):1155-60
pubmed: 16893130
Epigenet Insights. 2022 Oct 15;15:25168657221130041
pubmed: 36262691
Nat Rev Cardiol. 2013 Jul;10(7):387-96
pubmed: 23670612
Science. 1997 Feb 14;275(5302):964-7
pubmed: 9020076
Undersea Hyperb Med. 2004 Spring;31(1):123-31
pubmed: 15233168
Compr Physiol. 2015 Jul 1;5(3):1027-59
pubmed: 26140708
J Vasc Surg. 2000 Jan;31(1 Pt 2):S1-S296
pubmed: 10666287
J Cardiovasc Surg (Torino). 2013 Dec;54(6):663-9
pubmed: 24126504
Vasc Health Risk Manag. 2018 Apr 26;14:63-74
pubmed: 29731636
Circulation. 2006 Dec 12;114(24):2581-3
pubmed: 17159073
Circ Res. 2006 May 12;98(9):1194-202
pubmed: 16574905
J Vasc Surg. 1992 Jul;16(1):54-9
pubmed: 1619725
Stem Cells. 2018 Feb;36(2):161-171
pubmed: 29226477
Cardiovasc Res. 2004 Jan 1;61(1):132-42
pubmed: 14732210
J Am Coll Cardiol. 2013 Apr 23;61(16):1686-7
pubmed: 23500215
J Diabetes Complications. 2017 Jul;31(7):1109-1114
pubmed: 28479156
BMC Res Notes. 2016 Dec 9;9(1):508
pubmed: 27938397
Circ Cardiovasc Interv. 2016 Feb;9(2):e001946
pubmed: 26858079
Vasc Health Risk Manag. 2007;3(2):229-34
pubmed: 17580733
Lancet. 2002 Aug 10;360(9331):427-35
pubmed: 12241713
Life (Basel). 2022 May 31;12(6):
pubmed: 35743853
Int J Mol Sci. 2020 Nov 26;21(23):
pubmed: 33256237
Tissue Eng Regen Med. 2018 Nov 15;16(1):59-68
pubmed: 30815351
BMC Cardiovasc Disord. 2010 Aug 05;10:35
pubmed: 20687927
Schweiz Med Wochenschr. 1991 Mar 23;121(12):397-412
pubmed: 1709294
Cells. 2020 Jan 23;9(2):
pubmed: 31979244
J Neurobiol. 2002 May;51(2):85-100
pubmed: 11932951
Am J Physiol Heart Circ Physiol. 2003 Apr;284(4):H1230-9
pubmed: 12505879
Stem Cells Int. 2018 May 24;2018:7528464
pubmed: 29977308
Circulation. 2004 Mar 30;109(12):1543-9
pubmed: 15023891
J Diabetes Complications. 2014 Mar-Apr;28(2):214-8
pubmed: 24332936
Am Heart J. 2009 Jul;158(1):53-60.e1
pubmed: 19540392
J Vasc Surg. 2011 Feb;53(2):445-53
pubmed: 21030198
Am Fam Physician. 1999 Apr 1;59(7):1899-908
pubmed: 10208708
J Vasc Surg. 2003 Feb;37(2):316-22
pubmed: 12563201
Diabetes Metab Res Rev. 2014 Oct;30(7):623-34
pubmed: 24638886
J Mol Cell Cardiol. 2012 Jan;52(1):105-12
pubmed: 22047808
JAMA. 2001 Sep 19;286(11):1317-24
pubmed: 11560536
MMWR Morb Mortal Wkly Rep. 2005 Nov 18;54(45):1158-60
pubmed: 16292250
Vasc Med. 2008 Aug;13(3):281-91
pubmed: 18687766
Indian J Radiol Imaging. 2019 Oct-Dec;29(4):397-403
pubmed: 31949342
West J Med. 2000 Jul;173(1):60-3
pubmed: 10903303